Catalog No.
DHF78601
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Mucin-5 subtype AC, tracheobronchial, Gastric mucin, Mucin-5AC, TBM, MUC-5AC, Tracheobronchial mucin, Major airway glycoprotein, MUC5AC, MUC5
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P98088
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
NOE-102, NPC-1C, CAS: 1092658-06-4
Clone ID
Ensituximab
Note
For research use only. Not suitable for clinical or therapeutic use.
Translational research in pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011., PMID:21386635
Novel agents in early phase clinical studies on refractory pancreatic cancer., PMID:22406592
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer., PMID:27449137
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer., PMID:32303539
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial., PMID:36602796
Translational research in pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011, PMID: 21386635
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer, PMID: 27449137
Novel agents in early phase clinical studies on refractory pancreatic cancer, PMID: 22406592
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer, PMID: 32303539
For research use only. Not for human or drug use.
